NasdaqGM:LGNDPharmaceuticals
Ligand Pharmaceuticals (LGND) Is Up 8.1% After Swinging to Profit and Filing New Equity Shelf - What's Changed
In late February 2026, Ligand Pharmaceuticals reported a sharp improvement in fourth-quarter and full-year 2025 results, turning prior-year losses into net income of US$44.78 million for the quarter and US$124.45 million for the year, while reiterating 2026 revenue guidance of US$245 million to US$285 million.
At the same time, the company moved to broaden its financing and capital-raising options by filing a US$100 million at-the-market common stock offering and an omnibus shelf...